Retirement of Jon Lamb

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) independent director Jon Lamb today retired from the board following his announcement at the ASM that he would be stepping down once a new independent director had been appointed. This is in conjunction with today’s appointment of Andrew Lane to the Board.

Chair David Flacks said: “On behalf of the Board I would like to extend my thanks to Jon for his outstanding service during his 11-year tenure. His deep industry knowledge and experience has enabled him to make a significant contribution to the growth and success of AFT, and it has been a privilege to work alongside him.”

Released for and on behalf of AFT Pharmaceuticals limited by Malcolm Tubby, Chief Financial Officer.

May 1, 2024

AFT Licenses Maxigesic® IV in Brazil

We are delighted to announce our partnership with Brazil’s Halex Istar, and to be exclusively responsible for distributing its Maxigesic IV in Brazi…

Read More

April 24, 2024

AFT, Massey Ventures, Gilles McIndoe to develop scar treatment

AFT collaborate with Massey Ventures and Gilles McIndoe to begin the development of a topical treatment for keloid and hypertrophic scarring….

Read More

March 5, 2024

AFT makes further progress in international markets

AFT Pharmaceuticals provides an update on recent progress it has made in international markets….

Read More